Busonid® (Budesonide 200 mcg and 400 mcg) to Treat Asthma Not Controlled or Partially Controlled

NCT ID: NCT02853578

Last Updated: 2019-07-08

Basic Information

• Recruitment Status: SUSPENDED
• Clinical Phase: PHASE3
• Total Enrollment: 80 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-12-31
• Study Completion Date: 2020-12-31

Brief Summary

National clinical trial, phase III, multicenter, single-arm, efficacy study, 80 participants of both sexes, aged equal or more than 12 and less than 65 years. The group will use Busonid® (budesonide 200mcg and 400mcg) one application (inhalation) of 200 mcg every 12 hours (400mcg / day). During follow-up visits if the participant has not shown an increase in forced expiratory volume in one second greater than 12% and greater than 0,20L or 200ml in spirometry compared with baseline visit, will increase the dose to 800 mcg / day (2x 400 mcg day).

The study aims to revalidate by the National Health Surveillance Agency (ANVISA) the registration of the drug Busonid® which there is a vast scientific literature on the pre-clinical and clinical evidence that the efficacy and safety of budesonide. Thus, outlined is a single-arm study, which is applied to the study of the group of participants the same intervention for a certain period and the participants are evaluated for response.

Detailed Description

Busonid® is composed of budesonide and has two performances of 200mcg and 400mcg. It is a corticosteroid hormone with topical anti-inflammatory activity. The slow and continuous release of budesonide in the airways due to their esterification and their short plasma half life increases the selectivity of the corticosteroid to the airways, in patients with asthma, inhaled corticosteroids have a broad spectrum of anti-inflammatory effects, such as reducing the number of inflammatory cells in the lungs and inhibiting the synthesis and release of cytokines and other inflammatory mediators.

Conditions

Asthma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Busonid (budesonide 200mcg and 400mcg)

It´s a capsule with inhalatoin powder composed of budesonide 200mcg or 400mcg. The experimental drug will be dispensed in a cartridge containing 60 capsules of 200 mcg or 400 mcg and an inhaler. It should be stored at room temperature (between 15 and 30°C) and protected from moisture.

Regarding the dosage, the 80 study participants will perform an inhalation 200mcg every 12 hours (400 mcg / day). During follow-up visits (V1 and V2) the attending physician will assess the need for increased PSI dose to 400 mcg every 12 hours (800mcg / day). Study participants should rinse the mouth with water and / or brush your teeth immediately after use of the drug.

The duration of treatment may be 12 weeks.

Group Type: EXPERIMENTAL

Busonid (budesonide 200mcg and 400mcg)

Intervention Type: DRUG

cartridge containing 60 tablets of 200 mcg or 400 mcg and an inhaler;

1 application (inhalation) of 200mcg every 12 noon (400 mcg / day). During the visits of monitoring (V1 and V2) the doctor in charge assess the need to increase the dose of PSI 400mcg for every 12 hours (800mcg / day); treatment for 12 weeks.

Interventions

Busonid (budesonide 200mcg and 400mcg)

cartridge containing 60 tablets of 200 mcg or 400 mcg and an inhaler;

1 application (inhalation) of 200mcg every 12 noon (400 mcg / day). During the visits of monitoring (V1 and V2) the doctor in charge assess the need to increase the dose of PSI 400mcg for every 12 hours (800mcg / day); treatment for 12 weeks.

Intervention Type: DRUG

Other Intervention Names

Busonid

Eligibility Criteria

Inclusion Criteria

• Uncontrolled asthma diagnosis or partially controlled in according to the Guidelines of the Brazilian Society of Pneumology and Phlebology for Asthma Management - 2012;
• Capacity of survey participants or legal guardians to understand and consent to the participation of the research participant in this clinical study, expressed by signing the informed consent form;
• Ability of children survey participants 18 years understand and nod their participation in this clinical study, manifested by signing the informed assent form;
• Baseline forced expiratory volume in one second in screening visit between 55% and 85% of predicted value (before bronchodilator use), including the extremes (ensuring that the lung function test has been performed properly);
• Increase of 12% and 200 ml of forced expiratory volume in one second after the reversibility test at screening visit / initiation of treatment.

Exclusion Criteria

• Diagnosis of pneumonia, pneumothorax, pneumomediastinum, COPD, pulmonary tuberculosis, deficiency α1anti antitrypsin, lung mycosis (blastomycosis, histoplasmosis), bronchiectasis, pulmonary cystic fibrosis or other significant respiratory disease, according to the investigator;
• Pneumothorax history, pulmonary tuberculosis, lung mycosis (blastomycosis, histoplasmosis) and COPD;
• Immunosuppressive therapy;
• Survey participants with immunosuppression of any kind;
• Thoracic surgery history or any prior neoplastic process of the lung;
• Significant heart disease;
• Four or more systemic corticosteroid courses in the last 12 months;
• Participants who have needed hospitalization or care in the emergency room or emergency service (duration> 12 hours) to airway obstruction control (for exacerbation of asthma), at least once within the last three (03) months;
• History of asthma crisis with risk of death;
• Ventilatory support needs due to respiratory failure secondary to asthma within the past five (05) years;
• Infection of the upper respiratory tract or lower (viral or bacterial) within the last four (04) weeks prior to study entry;
• Any finding of clinical observation (clinical evaluation / physical) that is interpreted by the medical researcher as a risk to the research participant in the clinical study;
• Known hypersensitivity to drug components used during the study;
• Use of forbidden drugs in the clinical study described in Protocol;
• Smokers and former smokers;
• HIV infection, whether on antiretroviral treatment;
• History of abuse of illicit drugs;
• Disorders diagnosis of hypothalamic-pituitary-adrenal axis (hypocortisolism or hypercortisolism);
• Presence of severe obstruction of lung airflow that may present a risk of death;
• Women in reproductive age who do not agree to use hormonal or barrier methods of contraception; except the participants declared that they perform sexual practices or exercise them not to reproductive form;
• Female participants in a period of pregnancy or breastfeeding;
• Clinical trial protocols of participation in the last twelve (12) months (CNS Resolution 251 of August 7, 1997, Part III, sub-item J), unless the investigator considers that there may be a direct benefit to it;
• Family relationship to the second degree or bond with employees or employees of Sponsor and Research Center.

• Minimum Eligible Age: 12 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Ache Laboratorios Farmaceuticos S.A.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Elie Fiss

Role: PRINCIPAL_INVESTIGATOR

Multidisciplinary Studies Center CEPES of the ABC Medical School

Locations

Centro de Estudos Multidisciplinar CEPES da Faculdade de Medicina do ABC

Santo André, São Paulo, Brazil

Centro de Pesquisa do Hospital Nipo Brasileiro

São Paulo, , Brazil

Centro de Pesquisa em Pneumologia da Santa Casa de São Paulo

São Paulo, , Brazil

Centro Paulista de Investigação Clínica - CEPIC

São Paulo, , Brazil

IMA Brasil - Instituto de Medicina Avançada

São Paulo, , Brazil

Countries

Brazil

Other Identifiers

ACH-BSN-03(14/14)

Identifier Type: -

Identifier Source: org_study_id